Viagra for women? Drug developed as antidepressant effective in treating low libidoNovember 16, 2009Pooled results from three separate clinical trials of flibanserin, a drug originally created as an antidepressant, show it is effective in treating women with acquired hypoactive sexual desire disorder. These trials were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire. CHAPEL HILL - The drug flibanserin, which was originally created as an antidepressant, is effective in treating women with low libido, pooled results from three separate clinical trials have found. These trials were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire, said John M. Thorp Jr., M.D., McAllister distinguished professor of obstetrics and gynecology at the University of North Carolina at Chapel Hill School of Medicine and the principal investigator for North America in the studies. "Flibanserin was a poor antidepressant," Thorp said. "However, astute observers noted that it increased libido in laboratory animals and human subjects. So, we conducted multiple clinical trials and the women in our studies who took it for hypoactive sexual desire disorder reported significant improvements in sexual desire and satisfactory sexual experiences. "It's essentially a Viagra-like drug for women in that diminished desire or libido is the most common feminine sexual problem, like erectile dysfunction is in men," Thorp said. Studies have shown that the prevalence of hypoactive sexual desire disorder in the U.S. ranges from 9 percent to 26 percent of women, depending on age and menopausal status. Flibanserin is currently an investigational drug and is available only to women taking part in clinical trials. The results reported here were presented Monday, Nov. 16, at the Congress of the European Society for Sexual Medicine in Lyon, France. The presentation was given by Elaine E. Jolly, M.D., overall principal investigator and a professor at the University of Ottawa in Canada. Jolly, Thorp and colleagues pooled data from four clinical trials of flibanserin conducted in the U.S., Canada and Europe. A total of 1,946 pre-menopausal women ages 18 and older were randomized to receive either flibanserin or placebo for 24 weeks, with 4 weeks of pre-treatment baseline measurement and 4 weeks of post-treatment follow-up. Initially, four different dosing regimens were used in the trials: 25 milligrams twice a day, 50 milligrams once a day at bedtime, 50 milligrams twice a day and 100 milligrams once a day at bedtime. The dosing regimens totaling 50 milligrams a day were not effective while the regimens totaling 100 milligrams were. So, the results being reported are from only three of the four trials and are based on the 100 milligrams once a day dosing regimen only. The trials measured mean changes from baseline on the following six variables as reported by the women each week: number of satisfying sexual events (SSE), electronic diary (eDiary) desire score, female sexual function index (FSFI) desire domain score, FSFI total score, female sexual distress scale-revised (FSDR-R), and FSDR-R Item 13 (which focuses specifically on desire/libido). The researchers concluded that treatment with 100 milligrams of flibanserin once a day was associated with significant improvements versus placebo in the number of satisfying sexual events (SSE) reported, sexual desire (as measured by eDiary and FSFI desire domain), a reduction in distress associated with sexual dysfunction (as measured by FSDS-R and its Item 13), and sexual functioning as measured by FSFI. "These results point to a novel approach to pharmacologic treatment of the sexual problem that plagues reproductive age women the most, and may over time prove to be an effective treatment without the side effects of androgen replacement therapy, which is the only treatment currently available," Thorp said. The trials were funded by Boehringer Ingelheim Pharmaceuticals, the manufacturer of flibanserin. University of North Carolina at Chapel Hill School of Medicine |
|||||||||||||||||||||
| Related Sexual Desire Current Events and Sexual Desire News Articles Workplace BPA exposure increases risk of male sexual dysfunction High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals. Drug shows promise in treating dangerous complication of erectile disorder Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Men experience sexual dysfunction during hepatitis C therapy Sexual impairment is common among men with chronic hepatitis C undergoing antiviral therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. Female supervisors more susceptible to workplace sexual harassment Women who hold supervisory positions are more likely to be sexually harassed at work, according to the first-ever, large-scale longitudinal study to examine workplace power, gender and sexual harassment. Partner issues significantly influence women's sexual activity in later years, UCSF study shows As a woman gets older, physical problems are less likely to influence whether she is sexually active than her partner's health or interest in sex. Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer. Horphag's Prelox provides over-the-counter solution For couples worldwide, erectile dysfunction (ED) is one of the leading contributors to a man's inability to perform. As millions of men in America each year look for a solution, many seek alternative treatments to prescription medications and surgery that may have dangerous side effects. Couples more likely to divorce if spouse develops cervical or testicular cancer In the largest and most rigorous study to date investigating how cancer influences divorce, Norwegian researchers have found that marriages are no more likely than normal to break down unless a spouse develops cervical or testicular cancer. Sexual function affected by stem cell transplant according to long-term study A long-term study found that a type of stem cell transplant used for patients with life-threatening diseases, such as leukemia and lymphoma, results in decreased sexual function and activity for recipients. Low libido in menopause linked to trouble sleeping Women whose sexual desire diminishes during menopause are more likely to report disturbed sleep, depression symptoms, and night sweats. More Sexual Desire Current Events and Sexual Desire News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||